Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema

Subcutaneous C1‐inhibitor (HAEGARDA, CSL Behring), is a US Food and Drug Administration (FDA)‐approved, highly concentrated formulation of a plasma‐derived C1‐esterase inhibitor (C1‐INH), which, in the phase III Clinical Studies for Optimal Management in Preventing Angioedema with Low‐Volume Subcuta...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:CPT Pharmacometrics Syst Pharmacol
Egile Nagusiak: Zhang, Ying, Tortorici, Michael A., Pawaskar, Dipti, Pragst, Ingo, Machnig, Thomas, Hutmacher, Matthew, Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Longhurst, Hilary, Sidhu, Jagdev
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5869560/
https://ncbi.nlm.nih.gov/pubmed/29316335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12271
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak